Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity

Journal of Autoimmunity

Volumn 36, Issue 3-4, 2011, Pages 201-209

  Baugh, Mark ^a   Black, Darcey ^a   Westwood, Paul ^a   Kinghorn, Emma ^a   McGregor, Kieran ^a   Bruin, John ^a   Hamilton, William ^a   Dempster, Maureen ^a   Claxton, Christopher ^a   Cai, Jiaqiang ^a   Bennett, Jonathan ^a   Long, Clive ^a   Mckinnon, Heather ^a   Vink, Paul ^b   Hoed, Leontien den ^b   Gorecka, Monika ^b   Vora, Kalpit ^c   Grant, Ethan ^c   Percival, M David ^d   Boots, A Mieke H ^b   van Lierop, Marie José ^b   more..

^a MSD   (United Kingdom)

^b MSD   (Netherlands)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MERCK FROSST CENTRE FOR THERAPEUTIC RESEARCH   (Canada)

Author keywords

Cathepsin; Collagen induced arthritis; Experimental autoimmune encephalitis; Protease; T cell

Indexed keywords

1 METHYL 6 [4 [2 [1 (OXAZOL 2 YLMETHLY)PIPERIDIN 4 YL]ETHOXY] 3 (TRIFLUOROMETHYL)PHENYL] 1H IMIDAZO[4,5 C]PYRIDINE 4 CARBONITRILE; CATHEPSIN S; CATHEPSIN S INHIBITOR; CYCLOSPORIN; CYTOKINE; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN G2A; PREDNISOLONE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNITY; C57BL 6 MOUSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SPLEEN CELL; TH1 CELL; TH17 CELL; TRANSGENIC MOUSE;

ADMINISTRATION, ORAL; ANIMALS; ANTIGEN-PRESENTING CELLS; ARTHRITIS, EXPERIMENTAL; AUTOIMMUNE DISEASES; CATHEPSINS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED DBA; PIPERIDINES; PROTEASE INHIBITORS; PYRIDINES; TH1 CELLS;

EID: 79954784781     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2011.01.003     Document Type: Article

References (42)

1. Panayi G.S., Lanchbury J.S., Kingsley G.H. The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum 1992, 35:729-735.
2. Stinissen P., Raus J., Zhang J. Autoimmune pathogenesis of multiple sclerosis: role of autoreactive T lymphocytes and new immunotherapeutic strategies. Crit Rev Immunol 1997, 17(1):33-75.
3. Annunziato F., Cosmi L., Liotta F., Maggi E., Romagnani S. Type 17 T helper cells - origins, features and possible roles in rheumatic disease. Nat Rev Rheumatol 2009, 5:325-331.
4. Aranami T., Yamamura T. Th17 cells and autoimmune encephalomyelitis (EAE/MS). Allergol Int 2008, 57:115-120.
5. Hsieh C., deRoos P., Honey K., Beers C., Rudensky A.Y. A role for cathepsin L and cathepsin S in peptide generation for MHC class II presentation. J Immunol 2002, 168:2618-2625.
6. Plüger E.B.E., Boes M., Alfonso C., Schröter C.J., Kalbacher H., Ploegh H.L., et al. Specific role for cathepsin S in the generation of antigenic peptides in vivo. Eur J Immunol 2002, 32:467-476.
7. Nakagawa T.Y., Brissette W.H., Lira P.D., Griffiths R.J., Petrushova N., Stock J., et al. Impaired invariant chain degradation and antigen presentation and diminished collagen-induced arthritis in cathepsin S null mice. Immunity 1999, 10:207-217.
8. Riese R.J., Wolf P.R., Brömme D., Natkin L.R., Villadangos J.A., Ploegh H.L., et al. Essential role for cathepsin S in MHC class II-associated invariant chain processing and peptide loading. Immunity 1996, 4:357-366.
9. Shi G.P., Villadangos J.A., Dranoff G., Small C., Gu L., Haley K.J., et al. Cathepsin S required for normal MHC class II peptide loading and germinal center development. Immunity 1999, 10:197-206.
10. Villadangos J.A., Riese R.J., Peters C., Chapman H.A., Ploegh H.L. Degradation of mouse invariant chain: roles of cathepsins S and D and the influence of major histocompatibility complex polymorphism. J.Exp Med 1997, 186:549-560.
11. Villadangos J.A. Presentation of antigens by MHC class II molecules: getting the most out of them. Mol Immunol 2001, 38:329-346.
12. Driessen C., Bryant R.A., Lennon-Duménil A.M., Villadangos J.A., Bryant P.W., Shi G.P., et al. Cathepsin S controls the trafficking and maturation of MHC class II molecules in dendritic cells. J Cell Biol 1999, 147:775-790.
13. Shi G.P., Bryant R.A., Riese R., Verhelst S., Driessen C., Li Z., et al. Role for cathepsin F in invariant chain processing and major histocompatibility complex class II peptide loading by macrophages. J Exp Med 2000, 191:1177-1186.
14. Beers C., Honey K., Fink S., Forbush K., Rudensky A. Differential regulation of cathepsin S and cathepsin L in interferon gamma-treated macrophages. J Exp Med 2003, 197:169-179.
15. Lützner N., Kalbacher H. Quantifying cathepsin S activity in antigen presenting cells using a novel specific substrate. J Biol Chem 2008, 283:36185-36194.
16. Thurmond R.L., Sun S., Sehon C.A., Baker S.M., Cai H., Gu Y., et al. Identification of a potent and selective noncovalent cathepsin S inhibitor. J Pharmacol Exp Ther 2004, 308:268-276.
17. Riese R.J., Mitchell R.N., Villadangos J.A., Shi G.P., Palmer J.T., Karp E.R., et al. Cathepsin S activity regulates antigen presentation and immunity. J Clin Invest 1998, 101:2351-2363.
18. Yang H., Kala M., Scott B.G., Goluszko E., Chapman H.A., Christadoss P. Cathepsin S is required for murine autoimmune myasthenia gravis pathogenesis. J Immunol 2005, 174(3):1729-1737.
19. Saegusa K., Ishimaru N., Yanagi K., Arakaki R., Ogawa K., Saito I., et al. Cathepsin S inhibitor prevents autoantigen presentation and autoimmunity. J Clin Invest 2002, 110(3):361-369.
20. Desai S.N., White D.M., O'Shea K.M., Brown M.L., Cywin C.L., Spero D.M., et al. An orally active reversible inhibitor of cathepsin S inhibits human trans vivo delayed-type hypersensitivity. Eur J Pharmacol 2006, 24(538):168-174.
21. Irie O., Kosaka T., Kishida M., Sakaki J., Masuya K., Konishi K., et al. Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2. Bioorg Med Chem Lett 2008, 18(19):5280-5284.
22. Podolin P.L., Bolognese B.J., Carpenter D.C., Davis T.G., Johanson R.A., Fox J.H., et al. Inhibition of invariant chain processing, antigen-induced proliferative responses, and the development of collagen-induced arthritis and experimental autoimmune encephalomyelitis by a small molecule cysteine protease inhibitor. J.Immunol 2008, 180:7989-8003.
23. Verheijden G.F., Rijnders A.W., Bos E., Coenen-de Roo C.J., van Staveren C.J., Miltenburg A.M., et al. Human cartilage glycoprotein-39 as a candidate autoantigen in rheumatoid arthritis. Arthritis Rheum 1997, 40:1115-1125.
24. de Groot D.M., Vogel G., Dulos J., Teeuwen L., Stebbins K., Hamann J., et al. Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2. J.Immunol 2009, 183:4127-4134.
25. Joosten L.A., Helsen M.M., Saxne T., van De Loo F.A., Heinegard D., van Den Berg W.B. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J.Immunol 1999, 163:5049-5055.
26. Arbuckle W., Baugh M., Belshaw S., Bennett D.J., Bruin J., Cai J., et al. 1H-Imidazo[4,5-c]pyridine-4-carbonitrile as cathepsin S inhibitors: Separation of desired cellular activity from undesired tissue accumulation through optimization of basic nitrogen pka. Bioorg. Med. Chem. Lett. 2011, 21:932-935.
27. Mosmann T.R., Cherwinski H., Bond M.W., Giedlin M.A., Coffman R.L. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J.Immunol 1986, 136:2348-2357.
28. Steinman L. A brief history of T(H)17, the first major revision in the T(H)1/T(H)2 hypothesis of T cell-mediated tissue damage. Nat Med 2007, 13:139-145.
29. Williams R.O. Collagen-induced arthritis as a model for rheumatoid arthritis. Methods Mol Med 2004, 98:207-216.
30. Faure-André G., Vargas P., Yuseff M.I., Heuzé M., Diaz J., Lankar D., et al. Regulation of dendritic cell migration by CD74, the MHC class II-associated invariant chain. Science 2008, 322:1705-1710.
31. Park B., Brinkmann M.M., Spooner E., Lee C.C., Kim Y.M., Ploegh H.L. Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9. Nat Immunol 2008, 9:1407-1414.
32. Ziolkowska M., Koc A., Luszczykiewics G., Ksiezopolska-Pietrzak K., Klimczak E., Chwalinska-Sadowska H., et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin-sensitive mechanism. J Immunol 2000, 164:2832-2838.
33. Dittel B.N. CD4 T cells: balancing the coming and going of autoimmune-mediated inflammation in the CNS. Brain Behav Immun 2008, 22:421-430.
34. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., et al. FTY720, Sphingosine 1-phosphate receptor modulator, ameliorates Experimental Autoimmune Encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol 2005, 2:439-447.
35. Tonra J.R., Reiseter B.S., Kolbeck R., Nagashima K., Robertson R., Keyt B., et al. Comparison of the timing of acute blood-brain barrier breakdown to rabbit immunoglobulin G in the cerebellum and spinal cord of mice with experimental autoimmune encephalomyelitis. J Comp Neurol 2001, 430:131-144.
36. Sun D., Whitaker J.N., Huang Z., Liu D., Coleclough C., Wekerle H., et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001, 166:7579-7587.
37. Ford M.L., Evavold B.D. Specificity, magnitude, and kinetics of MOG-specific CD8+ T cell responses during experimental autoimmune encephalomyelitis. Eur J Immunol 2005, 35:76-85.
38. Kotake S., Udagawa N., Takahashi N., Matsuzaki K., Itoh K., Ishiyama S., et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J.Clin Invest 1999, 103:1345-1352.
39. Lubberts E., van den Bersselaar L., Oppers-Walgreen B., Schwarzenberger P., Coenen-de Roo C.J.J., Kolls J.K., et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF kappaB ligand/osteoprotegerin balance. J.Immunol 2003, 170:2655-2662.
40. Adamopoulos I.E., Bowman E.P. Immune regulation of bone loss by Th17 cells. Arthritis Res Ther 2008, 10(5):225-234.
41. Svelander L., Erlandsson-Harris H., Astner L., Grabowska U., Klareskog L., Lindstrom E., et al. Inhibition of cathepsin K reduces bone erosion, cartilage degradation and inflammation evoked by collagen-induced arthritis in mice. Eur J Pharmacol 2009, 613:155-162.
42. Reiser J., Adair B., Reinheckel T. Specialized roles for cysteine cathepsins in health and disease. J Clin Invest 2010, 120:3421-3431.